Svetlana Mishulin, MD
Internal Medicine · Troy, MINPI 1841308996
Payments from drug & device makers
Across 196 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$863
- UCB, Inc.$289
- Novo Nordisk$261
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$256
- Teva Pharmaceuticals USA, Inc.$228
- Sun Pharmaceutical Industries Inc.$206
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$170%
- Food & beverage$3,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$224
- INGREZZA$140
- DRIZALMA SPRINKLE$122
- EZALLOR SPRINKLE$122
- KAPSPARGO$122
How this compares
$3,849 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 875 | $238,462 |
| Austedo XrDeutetrabenazine | 12 | $172,820 |
| OzempicSemaglutide | 68 | $87,956 |
| TivicayDolutegravir Sodium | 31 | $52,643 |
| NuplazidPimavanserin Tartrate | 18 | $49,440 |
| TrulicityDulaglutide | 50 | $34,876 |
| XifaxanRifaximin | 18 | $31,053 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $28,225 |
| MyrbetriqMirabegron | 104 | $27,563 |
| Invega SustennaPaliperidone Palmitate | 11 | $27,148 |
| EpidiolexCannabidiol (Cbd) | 15 | $25,197 |
| BriviactBrivaracetam | 15 | $24,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $23,903 |
| FarxigaDapagliflozin Propanediol | 71 | $23,087 |
| XareltoRivaroxaban | 67 | $22,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $171 | $238,462875 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $228 | $172,82012 claims |
| Novo NordiskOzempic | $261 | $87,95668 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $71 | $51,94262 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $27 | $49,88678 claims |
| Acadia Pharmaceuticals IncNuplazid | $863 | $49,44018 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $88 | $31,05318 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $20 | $28,89280 claims |
| UCB, Inc.Briviact | $289 | $24,76915 claims |
| AstraZenecaFarxiga | $55 | $23,08771 claims |
| NovartisEntresto | $13 | $9,31731 claims |
| Eisai Inc.Fycompa | $25 | $8,84815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Troy
- Neil FraserTroy$14.3M
- Jay SandbergTroy$8.3M
- John CaladoTroy$198K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.